$183.42 Million in Sales Expected for BioScrip Inc (BIOS) This Quarter

Wall Street brokerages expect BioScrip Inc (NASDAQ:BIOS) to announce sales of $183.42 million for the current quarter, Zacks reports. Three analysts have provided estimates for BioScrip’s earnings, with the lowest sales estimate coming in at $176.06 million and the highest estimate coming in at $190.70 million. BioScrip reported sales of $217.81 million in the same quarter last year, which would suggest a negative year-over-year growth rate of 15.8%. The firm is scheduled to issue its next earnings results on Thursday, March 14th.

On average, analysts expect that BioScrip will report full-year sales of $702.60 million for the current financial year, with estimates ranging from $694.05 million to $716.00 million. For the next fiscal year, analysts forecast that the business will report sales of $746.31 million, with estimates ranging from $738.13 million to $755.00 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that follow BioScrip.

BioScrip (NASDAQ:BIOS) last issued its quarterly earnings data on Tuesday, November 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.07) by ($0.02). The firm had revenue of $181.00 million during the quarter, compared to analyst estimates of $171.35 million. During the same quarter in the prior year, the company earned ($0.12) EPS. The firm’s quarterly revenue was down 8.9% on a year-over-year basis.

BIOS has been the topic of several recent research reports. BidaskClub downgraded BioScrip from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, August 1st. Zacks Investment Research downgraded BioScrip from a “buy” rating to a “hold” rating in a research report on Monday, August 6th. Finally, Barrington Research restated a “buy” rating and issued a $4.00 price objective on shares of BioScrip in a research report on Wednesday, August 8th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $3.56.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Rhumbline Advisers lifted its position in BioScrip by 16.9% during the second quarter. Rhumbline Advisers now owns 126,878 shares of the company’s stock worth $372,000 after buying an additional 18,372 shares during the period. Bank of America Corp DE lifted its position in BioScrip by 8.5% during the second quarter. Bank of America Corp DE now owns 243,794 shares of the company’s stock worth $714,000 after buying an additional 19,096 shares during the period. Metropolitan Life Insurance Co. NY lifted its position in BioScrip by 77.3% during the second quarter. Metropolitan Life Insurance Co. NY now owns 45,013 shares of the company’s stock worth $132,000 after buying an additional 19,625 shares during the period. Mesirow Financial Investment Management Inc. lifted its position in BioScrip by 24.3% during the second quarter. Mesirow Financial Investment Management Inc. now owns 114,541 shares of the company’s stock worth $336,000 after buying an additional 22,382 shares during the period. Finally, BlackRock Inc. lifted its position in BioScrip by 0.4% during the third quarter. BlackRock Inc. now owns 7,616,244 shares of the company’s stock worth $23,610,000 after buying an additional 31,899 shares during the period. Hedge funds and other institutional investors own 84.99% of the company’s stock.

Shares of NASDAQ:BIOS traded down $0.05 on Friday, hitting $3.17. The company had a trading volume of 778,421 shares, compared to its average volume of 648,252. BioScrip has a 52-week low of $2.05 and a 52-week high of $3.36. The company has a market capitalization of $411.03 million, a P/E ratio of -7.20 and a beta of 0.42.

BioScrip Company Profile

BioScrip, Inc provides infusion solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. The company is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care.

Recommended Story: The Role of a Fiduciary and Individual Investors

Get a free copy of the Zacks research report on BioScrip (BIOS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioScrip (NASDAQ:BIOS)

Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply